The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
June 20th 2025
Oncology pharmacists are increasingly shaping patient care by integrating remote care, medication reconciliation, and artificial intelligence (AI), as well as by addressing drug shortages.
Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025
June 18th 2025In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.
Read More
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Read More
Assessing Prescriber Justification for Use of Outpatient Chemotherapy in the Acute Care Setting
This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.
Read More
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, Highlights Key Reasons to Attend OPC 2025
June 16th 2025Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.
Read More
You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Read More
Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC
June 11th 2025Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).
Read More
ASCO 2025: Asciminib Demonstrates Superiority Compared With Nilotinib in Ph+ CML-CP
June 11th 2025Asciminib shows superior tolerability over nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, enhancing treatment options and patient outcomes.
Read More